Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

NCT04213937 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

386

Enrollment

OTHER

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: nab-paclitaxel
DRUG: Topotecan

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences